The lymphopenia therapeutics market analysis considers sales from acquired lymphopenia and inherited lymphopenia product segments. The analysis also considers the sales of lymphopenia therapeutics in Asia, Europe, North America, and RoW.
In 2018, the acquired lymphopenia segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising incidence of diseases from various therapy areas such as blood cancer and autoimmune disorders will play a significant role in the acquired lymphopenia segment to maintain its market position.
The market report looks at factors such as increasing risk factors for lymphopenia. However, adverse effects associated with therapeutics, high cost of therapeutics, and stringent regulations may hamper the growth of the lymphopenia therapeutics industry over the forecast period.
Increasing risk factors for lymphopenia
High prevalence of risk factors such as inherited diseases, autoimmune disorders, blood cancer or blood diseases, and infectious diseases such as AIDS has led to the reduction in lymphocyte counts in blood of a patient. This increases the incidence of lymphopenia.
Pharmaceutical companies are investing in research and development activities to come up with effective and cost-efficient therapeutic drugs for lymphopenia. The availability of these drugs will lead to the expansion of the global lymphopenia therapeutics market at a CAGR of almost 4% during the forecast period.
Strategic alliances
Vendors are focusing on addressing the issues associated with high cost of research and development activities of therapeutic drugs by collaborating with pharmaceutical companies. They are also expanding their distribution networks by entering strategic alliances with other vendors. As a result, the development and commercialization of advanced therapies and drugs for lymphopenia is increasing. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global lymphopenia therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lymphopenia therapeutics manufacturers, that include:
AbbVie Inc.
Bristol-Myers Squibb Co.
CSL Ltd.
Gilead Sciences Inc.
GlaxoSmithKline PLC
Grifols S.A.
Johnson & Johnson Services Inc.
Merck & Co. Inc.
Novartis AG
Sanofi
Also, the lymphopenia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Key Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Comparison by product
Acquired lymphopenia - Market size and forecast 2018-2023
Inherited lymphopenia - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic comparison
North America - Market size and forecast 2018-2023
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Links:
Author: Copyright GlobeNewswire, Inc. 2016. All rights reserved. You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.
